Investigation Opened on Behalf of ADMA Biologics, Inc. (ADMA) Shareholders - Contact Levi & Korsinsky Ready to Announce with Confidence?
New York, New York--(Newsfile Corp. - April 6, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA Biologics, Inc.") concerning potential violations of the federal securities laws.
On the Q4 2025 earnings call, CEO Adam Grossman stated "ASCENIV achieved $363 million in net revenue, representing 51% year-over-year growth." Culper Research's short report contends ASCENIV only achieved its growth on the back of "classic channel stuffing." ADMA's annual report further claimed its commercial execution was "expected to accelerate demand utilization while maintaining cost discipline." Yet, Culper contends that members of ADMA's distributor attested that "underlying demand 'is not really growing.'"
The gap between the reported 20% revenue growth and the alleged 3% decline represents a substantial divergence. ADMA stock dropped sharply immediately following publication of the short-seller report on March 24, 2026 and throughout the following days.
If you suffered a loss on your ADMA Biologics, Inc. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/291255
Source: Levi & Korsinsky, LLP
Analyst, journalist, or company stakeholder? Sign up to receive news releases by email for Levi & Korsinsky, LLP or all companies in the Banking / Financial Services industry.
Investors in Disc Medicine, Inc. (IRON) Warned of Potential Securities Fraud - Contact Levi & Korsinsky Today
2026-04-06 12:39 AM EDT
Investigation Opened on Behalf of ADMA Biologics, Inc. (ADMA) Shareholders - Contact Levi & Korsinsky
2026-04-06 12:36 AM EDT
Potential Securities Fraud: Levi & Korsinsky Investigates Freshpet, Inc. (FRPT)
2026-04-06 12:19 AM EDT
Aug 29, 2025
September isn’t just back-to-school season—it’s back-to-business season. To see how companies prepare, we analyzed nearly 2,400 press releases from publicly traded companies on TMX Newsfile this summer (July 1 – August 28). The data reveals clear priorities. Financing & Capital Raises ( 25.5% ) and Product Launches & Updates ( 24.8% ) were the two most common strategies, together making up more than 50% of all announcements. But what really captures the market’s attention? Our viewership...
Economy, Business and Finance
Legal Service
Litigation and Regulation
Banking / Financial Services